This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

The X-Change Corporation Announces The Sacred Cow Production Presentation Of 'AMERICAN DRUG WAR 2: Cannabis Destiny,' A Film By Kevin Booth

DALLAS, April 16, 2013 /PRNewswire/ -- X-Change Corp. (NASDAQ OTC: XCHC), a U.S. Company specializing in cannabinoid formulation-based health and wellness solutions through its Phytiva Brand product lines, is excited to announce that 'AMERICAN DRUG WAR 2: Cannabis Destiny,' a film by Kevin Booth and produced by Sacred Cow Productions, will have its national release on June 6, 2013 in Denver, Colorado.  There will be a VIP screening event on Thursday, April 18, at Casselman's in Denver, Colorado to kick off the 'High Times' Cannabis Cup weekend.  The event also includes a Cloverleaf University Class taught by Ed Rosenthal as well as musical performance.

During the pre-production and research phase for 'AMERICAN DRUG WAR 2: Cannabis Destiny,' award-winning filmmaker Kevin Booth searched for a leading voice to shed light on medical cannabinoid formulations to help inform the general public.  The first installment of 'American Drug War' had premiered on Showtime in 2008 and featured interviews with University of Colorado Professor Robert Melamede, PhD, who has been working on FDA-track cannabinoid medicines through a publicly traded company, Cannabis Science, Inc., after decades of activism and scientific research.  Dr. Melamede continues his efforts to bring the actual cannabis plant derivative into the modern pharmacopeia and is again featured in the new film.

X-Change Corporation is picking up this film awareness effort and other projects that Cannabis Science had begun over the last twelve months, as Cannabis Science's sole direction has evolved to cannabinoid drug development, clinical trials, and FDA and other regulatory approval for its drugs, including its CS_TATI-1 formulation to treat Kaposi's Sarcoma. 

X-Change Corporation is also in the process of updating its website with actual testimonials and photographs of the profound efficacy of treating skin cancer and other critical ailments with topical and ingested cannabis extracts.  The precise launch date of the website with this information will be announced soon.

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 17,776.91 +93.33 0.53%
S&P 500 2,081.34 +12.58 0.61%
NASDAQ 4,997.4590 +5.5190 0.11%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs